Hows J, Szydlo R, Anasetti C, Camitta B, Gajewski J, Gluckman E
Department of Haematology, Hammersmith Hospital, London.
Bone Marrow Transplant. 1992;10 Suppl 1:102-6.
This report is divided into two parts. The first part is a retrospective analysis of 40 unrelated transplants [UD-BMT] for severe acquired aplastic anemia [SAA], performed at five transplant centers between 1981 and 1990. The second is an interim analysis of 15 UD-BMT for SAA compared with a matched cohort of 16 sibling transplants [ID-BMT] carried out since February 1989 using prospectively collected data provided by the IMUST Study Group. In the retrospective study the actuarial survival was 28% [+/- 15] with a median follow-up of 1485 [266-3890] days post BMT. Univariate analysis showed a considerable survival advantage for patients younger than 15 years at BMT [p = 0.03]. More recently patients entered in the IMUST Study showed an actuarial survival of 50% [+/- 27] for UD-BMT compared with 58% [+/- 31] for ID-BMT recipients. These data suggest that UD-BMT is a realistic option for paediatric patients with SAA. Although numbers are very small there is some indication from IMUST Study data that better patient selection and intensive BMT protocols may also improve the results of UD-BMT in young adult patients with SAA.
本报告分为两部分。第一部分是对1981年至1990年间在五个移植中心进行的40例非亲缘移植[非血缘骨髓移植(UD-BMT)]治疗严重获得性再生障碍性贫血[重型再障(SAA)]的回顾性分析。第二部分是对15例非血缘骨髓移植治疗重型再障的中期分析,并与1989年2月以来进行的16例同胞移植[同基因骨髓移植(ID-BMT)]的匹配队列进行比较,这些数据是使用IMUST研究组前瞻性收集的数据。在回顾性研究中,移植后中位随访1485天(266 - 3890天),精算生存率为28%(±15)。单因素分析显示,移植时年龄小于15岁的患者有显著的生存优势(p = 0.03)。最近,IMUST研究纳入的患者中,非血缘骨髓移植的精算生存率为50%(±27),而同基因骨髓移植受者为58%(±31)。这些数据表明,非血缘骨髓移植是重型再障患儿的一个现实选择。尽管病例数很少,但IMUST研究数据表明,更好的患者选择和强化的骨髓移植方案也可能改善成年重型再障患者非血缘骨髓移植的结果。